WO2017079369A3 - Novel antibodies - Google Patents

Novel antibodies Download PDF

Info

Publication number
WO2017079369A3
WO2017079369A3 PCT/US2016/060227 US2016060227W WO2017079369A3 WO 2017079369 A3 WO2017079369 A3 WO 2017079369A3 US 2016060227 W US2016060227 W US 2016060227W WO 2017079369 A3 WO2017079369 A3 WO 2017079369A3
Authority
WO
WIPO (PCT)
Prior art keywords
disclosed
novel antibodies
variants
low
iggs
Prior art date
Application number
PCT/US2016/060227
Other languages
French (fr)
Other versions
WO2017079369A2 (en
Inventor
Hongxing Zhou
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of WO2017079369A2 publication Critical patent/WO2017079369A2/en
Publication of WO2017079369A3 publication Critical patent/WO2017079369A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Disclosed in this invention are human IgG Fc variants sequences that demonstrate low and no binding activities to Fc gamma receptor. The disclosed Fc variants are useful for making Fc fusion proteins and/or IgGs where low or no Fc effector function of the mentioned molecules are desirable.
PCT/US2016/060227 2015-11-03 2016-11-03 Novel antibodies WO2017079369A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562250481P 2015-11-03 2015-11-03
US62/250,481 2015-11-03

Publications (2)

Publication Number Publication Date
WO2017079369A2 WO2017079369A2 (en) 2017-05-11
WO2017079369A3 true WO2017079369A3 (en) 2017-06-15

Family

ID=58662746

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/060227 WO2017079369A2 (en) 2015-11-03 2016-11-03 Novel antibodies

Country Status (1)

Country Link
WO (1) WO2017079369A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202206457A (en) * 2020-04-24 2022-02-16 美商美國禮來大藥廠 Pan-elr+ cxc chemokine antibodies for the treatment of respiratory disease
US20230303719A1 (en) 2022-03-03 2023-09-28 Yale University Humanized 3e10 antibodies, variants, and antigen binding fragments thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
WO2005047327A2 (en) * 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
US20060057701A1 (en) * 2004-07-30 2006-03-16 Arnon Rosenthal Antibodies directed against amyloid-beta peptide and methods using same
US20150110810A1 (en) * 2012-05-01 2015-04-23 Glaxosmithkline Llc Novel antibodies
US20150125458A1 (en) * 2013-11-06 2015-05-07 Janssen Biotech, Inc. Anti-CCL17 Antibodies

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
WO2005047327A2 (en) * 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
US20060057701A1 (en) * 2004-07-30 2006-03-16 Arnon Rosenthal Antibodies directed against amyloid-beta peptide and methods using same
US20150110810A1 (en) * 2012-05-01 2015-04-23 Glaxosmithkline Llc Novel antibodies
US20150125458A1 (en) * 2013-11-06 2015-05-07 Janssen Biotech, Inc. Anti-CCL17 Antibodies

Also Published As

Publication number Publication date
WO2017079369A2 (en) 2017-05-11

Similar Documents

Publication Publication Date Title
EP3621642A4 (en) Human monoclonal antibodies against lag3 and uses thereof
EP3733716A4 (en) Fusion protein dimer using antibody fc region as backbone and use thereof
WO2018017864A3 (en) Pvrig-binding agents and uses thereof
WO2017136820A3 (en) Fabs-in-tandem immunoglobulin and uses thereof
WO2017172260A8 (en) Binding proteins and methods of use thereof
WO2017184619A3 (en) Agonistic antibodies that bind human cd40 and uses thereof
WO2016191643A3 (en) Tigit-binding agents and uses thereof
WO2015112886A3 (en) Binding proteins and methods of use thereof
WO2017015623A3 (en) Multivalent and multispecific gitr-binding fusion proteins
WO2016077381A8 (en) Anti-interleukin-33 antibodies and uses thereof
IL279505A (en) Chimeric transmembrane proteins and uses thereof
EP3576789A4 (en) MONOMERIC HUMAN IgG1 Fc AND BISPECIFIC ANTIBODIES
WO2018081648A3 (en) Anti-mic antibidies and methods of use
WO2015168643A3 (en) Compositions and methods related to engineered fc constructs
WO2016061389A3 (en) Anti-alpha-synuclein antibodies and methods of use
WO2015197823A3 (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
EP3504234A4 (en) Heterodimeric immunoglobulin constructs and preparation methods thereof
EP3628049A4 (en) Tgf-beta receptor type ii fusion proteins and uses thereof
WO2016054598A3 (en) Antibodies that bind ebola glycoprotein and uses thereof
WO2016205531A3 (en) Anti-her2 antibodies and methods of use
EP3411504A4 (en) Anti-tnf antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
WO2016098079A3 (en) Compositions and methods for antibodies targeting bmp6
WO2015179658A3 (en) Anti-gpc3 antibodies and immunoconjugates
IL268704B (en) Formulations of human anti-rankl antibodies, and methods of using the same
WO2016094566A3 (en) Blood brain barrier receptor antibodies and methods of use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16862921

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16862921

Country of ref document: EP

Kind code of ref document: A2